Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27, H1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting and Unaudited Financial Results

Date of Board Meeting / Approval: November 02, 2026 (commenced at 05:45 PM IST, concluded at 07:00 PM IST)

Audit Opinion: Clean review opinion (unqualified)

Auditor’s Comment: The auditors stated that nothing has come to their attention that causes them to believe that the financial statements contain any material misstatement.

Key Financial Highlights [in Lakhs]

Standalone Results:

Revenue from Operations:

  • Q2 FY27: ₹3,003 (vs. ₹786 in Q2 FY25, +282.1% YoY)
  • H1 FY27: ₹6,995 (vs. ₹1,750 in H1 FY25, +299.7% YoY)

Total Income:

  • Q2 FY27: ₹5,365
  • H1 FY27: ₹11,723

Net Profit/(Loss):

  • Q2 FY27: Loss of ₹2,458 (vs. Loss of ₹7,597 in Q2 FY25, improvement of 67.7%)
  • H1 FY27: Loss of ₹4,556 (vs. Loss of ₹12,800 in H1 FY25, improvement of 64.4%)

EPS:

  • Q2 FY27: (₹0.76) per share
  • H1 FY27: (₹1.40) per share

Other Equity:

  • As of September 30, 2026: ₹140,393
  • As of March 31, 2026: ₹130,113

Cash and Cash Equivalents:

  • As of September 30, 2026: ₹203
  • As of March 31, 2026: ₹32

Debt: Not specifically disclosed in summary format

Consolidated Results:

Revenue from Operations:

  • Q2 FY27: ₹3,003
  • H1 FY27: ₹6,995

Total Income:

  • Q2 FY27: ₹5,365
  • H1 FY27: ₹11,723

Net Profit/(Loss):

  • Q2 FY27: Loss of ₹2,439 (attributable to owners)
  • H1 FY27: Loss of ₹4,517 (attributable to owners)

EPS:

  • Q2 FY27: (₹0.75) per share
  • H1 FY27: (₹1.39) per share

Other Equity:

  • As of September 30, 2026: ₹140,965
  • As of March 31, 2026: ₹130,637

Cash and Cash Equivalents:

  • As of September 30, 2026: ₹270
  • As of March 31, 2026: ₹116

Segment-wise Performance:

The Company has only one reportable business segment: 'Pharmaceutical Research and Development'.

Corporate Actions:

Preferential Warrant Allotment: On May 19, 2026, the Company allotted 3,85,10,000 warrants to Shanghvi Finance Private Limited on a preferential basis at an issue price of ₹155.80 each.

  • 25% of issue price (₹38.95 per warrant) received as subscription money
  • Balance 75% (₹116.85 per warrant) payable within 18 months from allotment date at time of conversion
  • Each warrant convertible into one equity share of ₹1 each

Other Significant Information:

Licensing Agreement Termination: During Q1 FY27 (quarter ended June 30, 2026), the Company and CMS Bridging DMCC mutually agreed to terminate the licensing agreement dated November 5, 2019. The Company refunded USD 2 million (₹1,889 lakhs) to CMS and recognized revenue of ₹2,921 lakhs relating to non-refundable consideration in the previous quarter.

Priority Review Voucher (PRV): During the previous year (FY26), the Company recognized income of ₹184,002 lakhs from the sale of a Priority Review Voucher granted by USFDA on February 03, 2026 for Sezaby®, which was sold on April 30, 2026 for USD 195 million. [Non-Recurring]

Labour Code Impact: The Government of India's New Labour Codes effective from November 21, 2025 resulted in an incremental cost of ₹1,236 lakhs recognized as an exceptional item during the previous year (FY26). [Non-Recurring]